Andreas Wildi, born 1972, is a medical doctor and an attorney at law.

He advises and represents companies, associations and NGOs in the life sciences and healthcare sector.

His main focus is on reimbursement and pricing as well as regulatory affairs relating to pharmaceuticals and medical devices.

Andreas Wildi studied medicine at the University of Zurich and received his doctorate (Dr. med. / MD). While working part-time as a doctor in a hospital, in international rescue services and assisting / substituting general practitioners, he completed his law studies at the University of St. Gallen HSG (lic. iur. HSG). Before being admitted to the bar, Andreas Wildi was a clerk at a Cantonal Court and a trainee in a recognized Zurich business law firm. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health BAG. Andreas Wildi deepened his market access expertise internationally as EMEA market access law director for a large multinational life sciences company. Andreas Wildi has been a partner at Walder Wyss in Zurich and Berne since 2015.

Andreas Wildi works in German, English and French. He is admitted to the bar before all courts in Switzerland and is a guest lecturer in pharmaceutical law at the Law Faculty of the University of Lucerne and at the University of Bern’s KPM Center for Public Management.

Significant Accomplishments

Walder Wyss successfully represented a pharmaceutical company before the Federal Supreme Court

Legalcommunity.ch Awards: Walder Wyss Receives Awards as Market Leading Firm and Labour Law Firm of the Year

Bavarian Nordic Acquires Emergent BioSolutions’ Travel Vaccines Portfolio

Adoption of revised laws on human genetic testing

Dr. Wild & Co. AG verkauft ihr Pharmageschäfts an die Verfora AG

Walder Wyss erhält die Who’s Who Legal Auszeichnungen Swiss Law Firm of the Year 2019 in den Bereichen «Data» und «Life Sciences»

Verdict of Swiss Federal Administrative Court C-595/2015, BAG-therapeutic-cross-comparison revoked

IPO Medartis an SIX Swiss Exchange

Metall Zug (SIX: METN) übernimmt Mehrheit an der Haag-Streit Holding AG

Neuer Partner bei Walder Wyss

• Impact of Medical Device Regualtions (MDR) Postponement on Swiss Medtech Industry

  By Andreas Wildi, Monja Sieber |June 2020

• Court Annuls FOPH Order Limiting Medicinal Product Price Increase

  By Andreas Wildi |December 2019

Additional Articles
Differenzierte WZW-Prüfung von pflanzlichen Arzneimitteln
Swiss pharmaceutical reimbursement and pricing: Ordinance Law Changes (KVV/KLV) as of January 2024: Today's Decision by the Swiss Federal Council (Bundesrat)
Handbuch zum Lebensmittel- und Gebrauchsgegenständerecht
Triennial review of medicines’ SL prices: Lessons learned from appeals won against the FOPH
The Revised Law on Human Genetic Testing
Zugang zu nicht zugelassenen/nicht gelisteten Arzneimitteln: Ein wahrer Irrgarten
Pharmaceutical Advertising 2022 - Switzerland
Kommentar zu Art. 5, 6 und 7a HMG
Inkrafttreten der geänderten Schweizer Medizinprodukteverordnung und deren Auswirkungen für die Medizintechnikindustrie
Das Life Sciences Law Review, Kapitel 24 – Schweiz
Pharmawerbung – Schweiz
Liberté de choix de la thérapie vs principe du caractère économique dans le domaine de la liste des spécialités
Therapiewahlfreiheit vs. Wirtschaftlichkeitsgebot im Bereich der Spezialitätenliste
Kapitel 16: Schweiz
Chapter 16: Switzerland
Update: Postponement of EU Medical Device Regulation implementation due to COVID-19
The Life Sciences Law Review Chapter 28 - Switzerland
Postponement of EU Medical Device Regulation implementation due to COVID-19
Die Abgrenzung von Lebensmitteln und Heilmitteln
Art. 40, 52, 52a KVG
Life Science Law Update
Life Science Law Update
Life Science Law Update
Life Science Law Update
Life Science Law Update
The Life Sciences Law Review - Chapter 29: Switzerland
Pharmawerbung – Schweiz
Arzneimittel sind kein knappes Gut
Limitierung von Arzneimitteln im Krankenversicherungsrecht: Wo wird die Grenze zur Rationierung überschritten?
Schränken hohe Arzneimittelpreise die ärztliche Therapiefreiheit ein?
Vertragshandbuch Pharma und Life Sciences – Besonderheiten des Schweizer Rechts, 10. Kapitel
Ärztliche Freiheit trotz Kontraindikationen?
Nebenwirkungen des Bundesratsenscheids, Kommentar in der NZZ zu Änderungen der Schweizer Arzneimittelpreisfestsetzung
Eine Wegleitung für die medizinische und pharmazeutische Praxis sowie für Behörden und Versicherer